Previous 10 | Next 10 |
Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments Acr...
SAN DIEGO , Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Evercore ISI 2 nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday , Dec. 3, 2019, in Boston . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , ...
My expectations for Neurocrine Biosciences ( NBIX ) have been somewhat restrained for 2019, as this biotech didn’t have a lot of clinical updates on the docket and I thought the Street had largely adjusted to the stronger-than-expected Ingrezza launch trajectory. The shares have perke...
Neurocrine's Ingrezza continues tardive dyskinesia dominance Neurocrine Biosciences ( NBIX ) continues to impress with Ingrezza's tardive dyskinesia launch, with the drug securing nearly $200M in revenue for Q3 '19: Figure 2: Ingrezza marches towards blockbuster status (> $250M/q...
SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the Journal of Clinical Psychopharmacology 1 published long-term data from the KINECT 4 Phase III, open-label study of INGREZZA ® (valbenazine) capsules, demonstrat...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Neurocrine Biosciences, Inc. (NBIX) Q3 2019 Earnings Conference Call November 4, 2019, 04:30 PM ET Company Participants Kevin Gorman - CEO Todd Tushla - Head of IR Matt Abernethy - CFO Eiry Roberts - CMO Eric Benevich - CCO Kyle Gano - Chief Business Development and Strateg...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q3 2019 Earnings Call Nov 4, 2019 , 4:30 p.m. ET Operator Continue reading
Neurocrine Biosciences (NASDAQ: NBIX ): Q3 GAAP EPS of $0.56 misses by $0.09 . Revenue of $222.09M (+46.4% Y/Y) beats by $10.78M . Press Release More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Healthcare stocks news,
SAN DIEGO , Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...